Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Dementia and Geriatric Cognitive Disorders

Volumn 23, Issue 1, 2006, Pages 22-28

  Cepek, Lukas ^a   Brechlin, Peter ^b   Steinacker, Petra ^a   Mollenhauer, Brit ^e   Klingebiel, Enrico ^b   Bibl, Mirko ^b   Kretzschmar, Hans A ^c   Wiltfang, Jens ^d   Otto, Markus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cerebrospinal fluid; Creutzfeldt Jakob disease; Proteome; Surrogate markers; Two dimensional polyacrylamide gel electrophoresis

Indexed keywords

PROTEIN 14 3 3; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; FEMALE; GENETIC ALGORITHM; HUMAN; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

14-3-3 PROTEINS; AGED; AGED, 80 AND OVER; CREUTZFELDT-JAKOB SYNDROME; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; ISOELECTRIC FOCUSING; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PROTEOMICS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SPINAL PUNCTURE; TAU PROTEINS;

EID: 33845728517     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096589     Document Type: Article

References (33)

1. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J: Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996;53:913-920.
2. Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM: Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188.
3. Will RG: Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993;49:960-970.
4. Steinhoff BJ, Racker S, Herrendorf G, et al: Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996;53:162-166.
5. Bieschke J, Giese A, Schulz-Schaeffer W, et al: Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 2000;97:5468-5473.
6. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
7. Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec 1998;73:361-365.
8. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr: An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000;48:395-398.
9. Zerr I, Bodemer M, Gefeller O, et al: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-40.
10. Aksamit AJ: Cerebrospinal fluid 14-3-3 protein: variability of sporadic Creutzfeldt-Jakob disease, laboratory standards, and quantitation. Arch Neurol 2003;60:803-804.
11. Beaudry P, Cohen P, Brandel JP, et al: 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999;10:40-46.
12. Green AJ, Thompson EJ, Stewart GE, et al: Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001;70:744-748.
13. Geschwind MD, Martindale J, Miller D, et al: Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60:813-816.
14. Harrington MG, Merril CR, Asher DM, Gajdusek DC: Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N Engl J Med 1986;315:279-283.
15. Choe LH, Green A, Knight RS, Thompson EJ, Lee KH: Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis 2002;23:2242-2246.
16. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-146.
17. Davidsson P, Sjogren M, Andreasen N, et al: Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002;109:128-133.
18. Zheng PP, Luider TM, Pieters R, et al: Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62:855-862.
19. Jiang L, Lindpaintner K, Li HF, et al: Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 2003;25:49-57.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Gorg A, Postel W, Gunther S: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1988;9:531-546.
22. Rabilloud T: Silver staining of 2-D electrophoresis gels. Methods Mol Biol 1999;112:297-305.
23. Harrington MG, Merril CR: Cerebrospinal fluid protein analysis in diseases of the nervous system. J Chromatogr 1988;429:345-358.
24. Zerr I, Pocchiari M, Collins S, et al: Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-815.
25. Green AJ: Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2002;28:427-440.
26. Steinacker P, Schwarz P, Reim K, et al: Unchanged survival rates of 14-3-3 gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol 2005;25:1339-1346.
27. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC: A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003;3:1495-1499.
28. Carrette O, Demalte I, Scherl A, et al: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-1494.
29. Steinacker P, Mollenhauer B, Bibl M, et al: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004;370:36-39.
30. Otto M, Wiltfang J, Cepek L, et al: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192-197.
31. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P: A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210-1214.
32. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E: Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2001;71:401-403.
33. Choe LH, Dutt MJ, Relkin N, Lee KH: Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 2002;23:2247-2251.